ThriveAI | $1,200,000 | (May 14, 2025)
Optimal Dynamics | $40,000,000 | (May 14, 2025)
Certified by Founder
Lodge
Remedy Plan Therapeutics
start up
United States
- Gaithersburg, MD
- 14/05/2025
- Unknown
- $18,000,000
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedy’s groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. We are advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Remedy's lead asset is RPT1G. With a favorable efficacy and tolerability profile, RPT1G will be advancing to the clinic in 2024.
- Industry Biotechnology
- Website https://remedyplan.com/
- LinkedIn https://www.linkedin.com/company/remedy-plan/
Complement 1 | $16,000,000 | (May 14, 2025)
Somite AI | Undisclosed Amount | (May 14, 2025)
Stackpack | $6,300,000 | (May 14, 2025)
Adopt AI | $6,000,000 | (May 14, 2025)
Saildrone | $60,000,000 | (May 13, 2025)
theom | $20,000,000 | (May 13, 2025)
Alt DRX | $2,700,000 | (May 13, 2025)
InBrain Pharma | $2,000,943 | (May 13, 2025)